GenMark

Among the updates provided at the conference on Wednesday, Luminex discussed development and plans for the Verigene II system, and GenMark touted its ePlex test portfolio.

The company said it expects revenues from its ePlex analyzers to go up approximately 110 percent year over year for Q4.

The test is the second of three panels intended to detect pathogens that cause the bloodstream infections that can lead to sepsis.

The firm had also applied for marketing clearance for its gram negative and fungal pathogen panels in October.

After six straight months of gains, the index saw a sharp drop in October that even positive earnings news could not stave off.

The firm beat analysts' revenue expectations for the quarter while its net loss was in line with predictions.

The firm has completed submissions for all three of its ePlex panels for diagnosis and management of bloodstream infections that can lead to sepsis.

Smaller multiplex molecular panels of five or fewer targets will be covered, while a determination of gastrointestinal panel coverage is expected soon.

The company beat the consensus Wall Street estimate on the top line but missed it on the bottom line. It placed 39 net new ePlex analyzer during the quarter.

It is the first of three ePlex molecular multiplex panels for the diagnosis and management of bloodstream infections that can lead to sepsis.